Hematology (MPN & CML)

  1. Bcr Abl Detection Test (Bcr Abl Qualitative)
    1. Indication: chronic myeloid leukemia
    2. Function: predict the effectivity of tyrosine kinase inhibitor/ TKI (imatinib, nilotinib, dasatinib)
    3. Sample: 6 cc whole blood EDTA in cold storage and must be receipt not more than 36 hours by KalGen at working days since phlebotomy
    4. Analyte: RNA (major – b2a2, major – b3a2, minor – e1a2, micro – c3a2)
    5. Method: reverse transcript PCR
    6. Interpretation: trans-location detected is eligible for TKI
    7. TAT: 7 working days
    8. Guideline: NCCN 1.2015 and ESMO
    9. External quality assurance: UKNEQAS 2014UKNEQAS 2014aUKNEQAS 2014b

  2. Bcr Abl Quantification Test (Bcr Abl Quantitative)
    1. Indication: chronic myeloid leukemia
    2. Function: evaluate the effectivity of tyrosine kinase inhibitor/ TKI (imatinib, nilotinib, dasatinib)
    3. Sample: 6 cc whole blood EDTA in cold storage and must be receipt not more than 36 hours by KalGen at working days since phlebotomy
    4. Analyte: RNA (major – b2a2, major – b3a2)
    5. Method: reverse transcript quantitative PCR
    6. Interpretation: bcr-abl/ abl < 0.1% is major molecular response and eligible to continue the TKI therapy
    7. TAT: 7 working days
    8. Guideline: NCCN 1.2015 and ESMO
    9. External quality assurance: International Scale by WHO

  3. Bcr Abl Mutation Test
    1. Indication: chronic myeloid leukemia
    2. Function: predict the effectivity of switching imatinib into nilotinib or dasatinib
    3. Sample: 6 cc whole blood EDTA in cold storage and must be receipt not more than 36 hours by KalGen at working days since phlebotomy
    4. Analyte: RNA (codon 315)
    5. Method: reverse transcript PCR
    6. Interpretation: wild type is eligible for TKI switching
    7. TAT: 7 working days
    8. Guideline: NCCN 1.2015 and ESMO

  4. JAK2 Mutation Test
    1. Indication: myeloproliferative neoplasm/ MPN (polycithaemia vera, essential thrombocythemia, primary myelofibrosis)
    2. Function: diagnose MPN and predict the effectivity of tyrosine kinase inhibitor/ TKI (ruxolitinib)
    3. Sample: 6 cc whole blood EDTA in cold storage and must be receipt not more than 36 hours by KalGen at working days since phlebotomy
    4. Analyte: RNA (codon 617)
    5. Method: reverse transcript PCR
    6. Interpretation: mutation in V617F is possibly MPN
    7. TAT: 7 working days
    8. Guideline: NCCN 1.2016 and ESMO
Advertisements